A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600–Mutant Solid Tumors
Clinton Yam(The University of Texas MD Anderson Cancer Center), Tara C. Gangadhar(University of Pennsylvania), Ravi K. Amaravadi(University of Pennsylvania), Lynn M. Schuchter(Eastern Cooperative Oncology Group), Ragini R. Kudchadkar, Phyllis A. Gimotty(University of Pennsylvania), Shujing Liu(University of Pennsylvania), Jennifer J.D. Morrissette(University of Pennsylvania), Khalida Wani(The University of Texas MD Anderson Cancer Center), Giorgos C. Karakousis(Hospital of the University of Pennsylvania), Naomi B. Haas(University of Pennsylvania), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Anna C. Pavlick(Cornell University), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Meghan Buckley(Main Line Health), Xiaowei Xu(University of Pennsylvania), Luke Walker(Cancer Research UK), Wanleng Deng(The University of Texas MD Anderson Cancer Center), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Michael T. Tetzlaff(The University of Texas MD Anderson Cancer Center), Jianhua Zhao(Southwest Petroleum University)
Cited by 38
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Guidelines for the use and interpretation of assays for monitoring autophagy
|Autophagy|2012|4.1k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k